Wedbush Cuts Earnings Estimates for TScan Therapeutics

Key Points

• Wedbush has cut its Q3 2025 earnings per share estimate for TScan Therapeutics to ($0.29), down from a prior estimate of ($0.27), while maintaining an "Outperform" rating and a price target of $7.00.
• The company's latest quarterly earnings report showed a loss of ($0.28) per share, matching analyst expectations, with revenues of $3.08 million, significantly surpassing consensus estimates.
• Institutional investors own approximately 82.83% of TScan Therapeutics, indicating strong backing from major financial players.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Analysts at Wedbush reduced their Q3 2025 earnings per share estimates for TScan Therapeutics in a report released on Tuesday, August 12th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.29) per share for the quarter, down from their prior forecast of ($0.27). Wedbush has a "Outperform" rating and a $7.00 price target on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics' Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.04) EPS, Q1 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($0.97) EPS and FY2028 earnings at ($0.91) EPS.

Several other brokerages have also issued reports on TCRX. Wall Street Zen raised TScan Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. HC Wainwright reduced their target price on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $7.80.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock opened at $1.81 on Friday. TScan Therapeutics has a 1-year low of $1.02 and a 1-year high of $6.23. The company has a current ratio of 7.06, a quick ratio of 8.55 and a debt-to-equity ratio of 0.18. The business has a 50-day moving average price of $1.67 and a two-hundred day moving average price of $1.67. The company has a market cap of $102.43 million, a P/E ratio of -1.66 and a beta of 0.99.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.28). The business had revenue of $3.08 million during the quarter, compared to the consensus estimate of $1.31 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%.

Hedge Funds Weigh In On TScan Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Catalyst Funds Management Pty Ltd bought a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $26,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $29,000. Quadrature Capital Ltd bought a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $33,000. Boothbay Fund Management LLC lifted its position in shares of TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company's stock worth $35,000 after buying an additional 8,121 shares in the last quarter. Finally, ProShare Advisors LLC bought a new position in shares of TScan Therapeutics during the 4th quarter worth approximately $40,000. Institutional investors own 82.83% of the company's stock.

Insiders Place Their Bets

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp purchased 1,388,794 shares of the company's stock in a transaction that occurred on Monday, May 19th. The shares were acquired at an average price of $1.20 per share, with a total value of $1,666,552.80. Following the transaction, the insider owned 6,746,141 shares in the company, valued at $8,095,369.20. The trade was a 25.92% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.35% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.